GHB (γ -hydroxybutyrate) is both a neurotransmitter and a drug of abuse (date-rape drug). We investigated the catabolism of this compound in perfused rat livers. Using a combination of metabolomics and mass isotopomer analysis, we showed that GHB is metabolized by multiple processes, in addition to its previously reported metabolism in the citric acid cycle via oxidation to succinate. A substrate cycle operates between GHB and γ -aminobutyrate via succinic semialdehyde. Also, GHB undergoes (i) β-oxidation to glycolyl-CoA + acetyl-CoA, (ii) two parallel processes which remove C-1 or C-4 of GHB and form 3-hydroxypropionate from C-2 + C-3 + C-4 or from C-1 + C-2 + C-3 of GHB, and (iii) degradation to acetyl-CoA via 4-phosphobutyryl-CoA. The present study illustrates the potential of the combination of metabolomics and mass isotopomer analysis for pathway discovery.
INTRODUCTION

GHB (γ -hydroxybutyrate) is a neurotransmitter derived from the transamination of GABA (γ -aminobutyrate). The known catabolism of GHB involves (i) conversion into succinic semialdehyde by a cytosolic NADP
+ dehydrogenase [1] and by a mitochondrial pyridine nucleotide-independent enzyme system [2] , and (ii) the oxidation of succinic semialdehyde to succinate, an intermediate of the CAC (citric acid cycle). Humans with an inborn disorder of succinic semialdehyde dehydrogenase have high GHB concentrations in their bodily fluids, mental retardation and suffer from seizures [3] . Mice deficient in succinic semialdehyde dehydrogenase fail to thrive and suffer from chronic epileptic seizures [4] . The identification of glycolate in the urine of humans with succinic semialdehyde dehydrogenase deficiency led Vamecq et al. [5] and Brown et al. [6] to hypothesize that GHB can undergo β-oxidation to acetyl-CoA. Furthermore, the identification of 2,4-dihydroxybutyrate and 3-hydroxypropionate in the urine of humans with succinic semialdehyde dehydrogenase deficiency led Brown et al. [6] to hypothesize that GHB can undergo α-oxidation. GHB is also a drug of abuse which, at millimolar concentrations in body fluids, causes amnesia and impairs the ability of the subject to exercise judgement (date-rape drug) [7] . The disposal of exogenous GHB in vivo is inhibited by ethanol [8] . GHB is used for the treatment of narcolepsy with associated cataplexy [9] .
We reported previously that 4-hydroxyacids, including GHB, are converted in liver into 4-phosphoacyl-CoAs, a new class of acyl-CoA esters [10, 11] . When generated from 4-hydroxyacids with more than four carbons, 4-phosphoacyl-CoAs undergo a series of reactions leading to 3-hydroxyacyl-CoAs, which are intermediates in the β-oxidation of fatty acids. The catabolism of 4-hydroxyacids with more than four carbons leads to acetyl-CoA, formate and, for odd-chain 4-hydroxyacids, propionyl-CoA. In mice deficient in succinic semialdehyde dehydrogenase, the brain and liver concentrations of 4-hydroxy-4-phosphobutyryl-CoA is 40-fold greater than in wild-type and heterozygote mice [10] .
The aim of the present study was to characterize the metabolism of GHB via the CAC and other processes, using a combination of metabolomics [12] [13] [14] and mass isotopomer analysis [15, 16] . (Mass isotopomers are designated M, M1, M2, . . . Mn where n is the number of heavy atoms in the molecule.) We report that, in addition to metabolism through the CAC, GHB is degraded by β-oxidation and by two parallel processes, which remove C-1 of GHB via α-oxidation, and C-4 of GHB via unknown mechanisms.
EXPERIMENTAL
Chemicals and reagents
General chemicals, [ 13 13 C 2 -labelled ethyl bromoacetate, which was reacted with the sodium salt of benzyl alcohol followed by DIBAL-H (di-isobutyl aluminium hydride) reduction to give the α-(benzyloxy)acetaldehyde. This was subjected to Wittig olefination using (ethoxycarbonylmethylene)triphenylphosphorane followed by hydrogenation and acid-catalysed lactonization as above to produce [3,4- 13 C 2 ]GHB lactone. The lactones were purified with silica flash chromatography using a 90:10 (v/v) hexane/ethyl acetate solvent system.
The purity of the labelled GHB lactones was assessed using 1 H-NMR and judged to be greater than 98 % pure. 13 C atoms in the molecules: (i) the mass of the parent ion at m/z 233 increased to 235 for both compounds, and (ii) the mass of ion at m/z 204 (C-1 + C-2 of GHB) increased from 204 to 206 with [1,2-13 C 2 ]GHB, but remained at 204 for [3,4- 13 C 2 ]GHB. The unlabelled and labelled GHB lactones were hydrolysed with 10 % excess NaOH at 60
• C for 1 h before use.
Animal experimentation
All experiments involving animals were performed in accordance with IACUC (Institutional Animal Care and Use Committee) guidelines at Case Western Reserve University.
Organ perfusions
Livers from overnight-fasted Sprague-Dawley rats were perfused [17] for 2 h with 150 ml of recirculating bicarbonate buffer containing 4 % (w/v) dialysed BSA (fraction V, fatty-acid-free; InterGen), 4 mM glucose with or without 2 mM GHB (unlabelled or 13 C 4 -, 1,2-13 C 2 -, 3,4-13 C 2 -or 2 H 6 -labelled). One liver was perfused with 2 mM unlabelled GHB in 100 % 2 H 2 O buffer. In some experiments, 10 mM ethanol or 5 mM glucuronolactone was added at 60 min. Rat hearts were perfused for 60 min in the Langendorff mode with 100 ml of recirculating buffer containing 3 % (w/v) BSA and 4 mM glucose with or without 1 mM [ 13 C 4 ]GHB. Livers and hearts were quick-frozen at the end of the perfusions.
Analytical procedures
The concentrations and 13 C-mass isotopomer distributions of CAC intermediates, glutamate [18] and CoA esters [10] were assayed as described previously. For the assay of GHB and its carboxylic acid metabolites, perfusate samples (200 μl) spiked with 0.2 μmol of [ 2 H 6 ]GHB internal standard were deproteinized with 2 ml of acetonitrile. After centrifugation and evaporation under N 2 , the residue was allowed to react with 100 μl of trimethylsilyl reagent and heated for 1 h at 60
• C. Then, 2 μl was injected into an Agilent 6890 gas chromatograph linked to a 5973 MSD mass spectrometer. The chromatograph was equipped with a 60 m Varian CP 9017 VF-5 capillary column. The carrier gas was helium (26.8 ml/min), and the injection mode was splitless. The injector temperature was set at 290
• C, and the transfer line was held at 290
• C. The column temperature was increased by 3
• C/min from 50 • C to 300
• C, where it was held for 10 min. The mass spectrometer was operated under electron impact ionization. The quadrupole and ion source temperatures were 150 and 230
• C respectively. The mass scan ranged from 50 to 700. The retention times of 3-hydroxypropionate, GHB, 2,4-dihydroxybutyrate and 3,4-dihydroxybutyrate were 25.2, 29.7, 37.4 and 38.3 min respectively.
The concentrations and labelling of formate and acetate were assayed as the pentafluorobenzyl derivatives by ammonianegative chemical ionization [19] . Because of the ubiquitous contamination of solutions with traces of unlabelled formate [20] , the labelling of formate is not expressed as molar percent enrichment. We present concentrations of M1 formate, after proper correction of the fraction of the M1 signal, which is derived from the natural enrichment of contaminant formate. In experiments with [ 2 H 6 ]GHB or with unlabelled GHB in 100 % 2 H 2 O buffer, the 2 H-mass isotopomer distribution of GHB was assayed by negative chemical ionization of the pentafluorobenzylacetyl derivative [21] .
Calculations and statistics
Correction of raw mass isotopomer profiles for natural enrichment at each mass was conducted using CORMAT software [22] . In perfusions with [ 13 C 4 ]GHB, relative anaplerosis was calculated as the enrichment ratio (M4 succinate)/(M4 GHB), because M4 succinate cannot be formed from recycling of label in the CAC. Statistical differences were tested using a paired Student's t test (GraphPad Prism version 3).
RESULTS
Uptake of GHB by the liver
The uptake of GHB by the perfused liver, starting with a 2 mM concentration, was linear with final concentrations above 1 mM at 120 min. Addition of 10 mM ethanol at 60 min significantly decreased the rate of GHB uptake from 205 + − 29 to 92 + − 34 nmol/min per g of dry weight (P < 0.05). Kaufman and Nelson [8] reported a similar effect of ethanol on GHB metabolism in vivo. In two perfusions, addition of 10 mM t-butanol, a nonmetabolizable alcohol, did not affect the rate of GHB uptake from 60 to 120 min (results not shown). This demonstrates that the inhibition of GHB uptake by ethanol requires ethanol oxidation. Kaufman and Nelson [1] reported that after injection of tracer [U- 14 C]GHB to two rabbits, the uptake of the tracer from the plasma was accelerated by an intravenous injection of glucuronate to one of the rabbits. This suggested the possibility that infusing glucuronate or glucuronolactone could treat humans intoxicated by GHB. In our experiments, the uptake of GHB (at millimolar concentration) by the perfused rat liver was not affected by 5 mM glucuronolactone. A similar negative effect of glucuronate on the clearance of a GHB load in rats was reported previously [23] .
Metabolism of GHB via the CAC
For livers perfused with [ 13 C 4 ]GHB, Table 1 shows the mass isotopomer distribution of CAC intermediates, related compounds (glutamate and GABA) and glucose. The metabolism of M4 GHB yields initially M4 succinate. Cycling of M4 succinate in the CAC yields M1 and M2 isotopomers of succinate. Dividing the M4 enrichment of succinate (7.6 %) by the M4 enrichment of GHB (95 %) yields the relative anaplerosis from GHB of 8 %. This represents the contribution of GHB to the catalytic intermediates of the CAC, which carry acetyl-CoA as it is oxidized. The M4 enrichment of succinyl-CoA was similar to that of succinate. This reflects the isotopic equilibration of succinate and succinyl-CoA through the activities of succinylCoA synthetase and succinyl-CoA hydrolase. The substantial abundances of M1 and M2 succinate reflect recycling of label in the CAC. Lastly, GABA was M4 labelled (59 %, Table 1 ). This high M4 enrichment reflects the reversibility of the GABA transaminase and GHB dehydrogenase at high GHB 
. This shows that carbon from anaplerotic GHB left the CAC via PEPCK (phosphoenolpyruvate carboxykinase) and followed the reactions of gluconeogenesis. Propionyl-CoA and methylmalonyl-CoA were substantially labelled (Table 1) , probably via reversal of the methylmalonyl-CoA mutase and propionyl-CoA carboxylase reactions [24] . Addition of ethanol did not significantly affect the mass isotopomer distribution of CAC intermediates and the anaplerosis from GHB (results not shown).
Cycling between GHB and succinic semialdehyde
To test for cycling between GHB and succinic semialdehyde, an intermediate in the formation of succinate and GABA, we ran one perfusion with unlabelled GHB in 100 % 2 H 2 O buffer, and a series of perfusions with an initial 2 mM [ 2 H 6 ]GHB in regular buffer. Our strategy was to test for gain or loss of 2 H in GHB. To optimize the measurement of the mass isotopomer distribution of GHB, we derivatized it with pentafluorobenzyl bromide and assayed the derivative by ammonia-negative chemical ionization [21] . The pentafluorobenzyl group of the derivative is lost as a neutral fragment by dissociative electron capture in the mass spectrometer source. Thus the isotopomer distribution is measured on the GHB ion, the natural M1 enrichment of which is low (4.5 %). In the perfusion with unlabelled GHB in 100 % 2 H 2 O buffer, the mass isotopomer distribution of perfusate GHB, corrected for natural enrichment, showed a progressive accumulation of M1 to M4 mass isotopomers ( Figure 1A ). The accumulation of the dominant M1 isotopomer follows a sigmoidal curve, which reflects two processes. Early in the experiment, because of the chiral specificity of alcohol dehydrogenase [25] , the oxidation of unlabelled GHB transfers an unlabelled hydrogen from the pro-R position on C-4 of GHB to the pro-4R position of NADH. Reduction of succinic semialdehyde to GHB would not introduce 2 H into GHB because NADH was initially unlabelled. However, as the experiment proceeds, glucose and CAC intermediates become extensively labelled from the deuterated perfusate. As a result, NADH becomes labelled on its 4R hydrogen via dehydrogenases of the same chirality as alcohol dehydrogenase (e.g. malate dehydrogenase, NAD-isocitrate dehydrogenase, phosphoglycerate dehydrogenase [26] and succinic semialdehyde dehydrogenase). This explains the delay in M1 labelling of GHB, which is most likely to be [4-R-2 H]GHB. The stereospecificity of the alcohol dehydrogenase requires an alternative explanation for the formation of M2 to M4 isotopomers of GHB in 100 % 2 H 2 O buffer. If [4-2 H]succinic semialdehyde undergoes non-enzymatic keto-enol tautomerization before being re-converted into GHB, two additional 2 H atoms from the buffer could be incorporated on C-3 of GHB (after reduction of succinic semialdehyde to GHB). Incorporation of 2 H into the pro-4S hydrogen of GHB could be effected during the transamination reaction by transfer from the enzyme general acid/base group. Alternatively, multiple 2 H atoms could be incorporated by partial β-oxidation and reversal (see below). The predominance of the increase in the M1 isotopomer of GHB ( Figure 1A) indicates that the cycling between GHB and succinic semialdehyde is more rapid than the keto-enol tautomerization at physiological pH.
In the perfusions with [ 2 H 6 ]GHB in normal buffer, we observed the release of M5 and M4 mass isotopomers of GHB in the perfusate ( Figure 1B) . The baseline proportions of M5 and M4 mass isotopomers result from the fact that commercial deuterated compounds are 98-99 % 2 H-labelled on each hydrogen. On the basis of the above rationale, the R hydrogen on C-4 of M5 GHB ( 
Metabolomics of GHB catabolism
We conducted metabolomic analyses of the final perfusates from livers perfused with buffer containing 0 or 2 mM GHB (unlabelled or [ 13 C 4 ]GHB). Figure 2 shows the analytical steps leading to the identification of GHB metabolites in the final perfusate of a liver that had been perfused for 120 min with recirculating buffer containing unlabelled GHB (initially 2 mM). A liver perfused without GHB served as control. The top panel of Figure 2 shows mirror images of low-resolution time profiles of mass spectrometric data (total ion current under electron ionization) of trimethylsilyl derivatives. High-resolution plotting of the data in areas of the scan where the signal was very low identified peaks in the GHB perfusion that appeared to be absent from, or present in very low amounts in, the control perfusion ( Figure 2, middle panels) . Processing of the data using NIST software identified 3-hydroxypropionate, 2,4-dihydroxybutyrate and 3,4-dihydroxybutyrate (Figure 2 , bottom panels), as well as 4-hydroxycrotonate (4-hydroxybutene-2-oate) (results not shown). The latter had been identified in the brain of rats injected with GHB [27, 28] .
Similar analyses from liver perfusions with [ 13 C 4 ]GHB led to the identification of labelled 3-hydroxypropionate (M3), 2,4-dihydroxybutyrate (M4), 3,4-dihydroxybutyrate (M4 as expected, but also M2), 4-hydroxycrotonate (M4), oxalate (M2) and glycolate (M2). Note that small amounts of unlabelled 3,4-dihydroxybutyrate, 3-hydroxypropionate, glycolate and oxalate were present in control experiments without GHB. Additional analyses demonstrated the formation of low concentrations of [ 13 C]formate and [ 13 C]acetate. These were assayed as pentafluorobenzyl derivatives under negative chemical ionization to minimize natural enrichment of the analytes. The very low labelling of free acetate (< 0.6 %) reflects a very low labelling of acetyl-CoA which could not be detected in the LC-MS/MS assay of acetyl-CoA because of the high M1 and M2 natural enrichments of acetyl-CoA (30 % and 12 % respectively). Some of the results gathered at this point were compatible with a β-oxidation of GHB to glycolate + acetyl-CoA as hypothesized by Vamecq et al. [5] .
To gain further insight into the catabolism of GHB, we conducted a series of liver perfusions with 1 mM unlabelled 4-hydroxycrotonate, a compound identified in the brain of rats injected with GHB [27, 28] . 4-Hydroxycrotonyl-CoA is a probable intermediate of the catabolism of GHB via β-oxidation. We reasoned that 4-hydroxycrotonate would be activated in the liver to 4-hydroxycrotonyl-CoA. This strategy allowed us to inject carbon in a metabolite pool, which is part of the putative β-oxidation of GHB. In livers perfused with 4-hydroxycrotonate, we observed the formation of 3-hydroxypropionate and of GHB ( Figure 3 ). The mass isotopomer distribution of some of these compounds is shown in Figure 5 . 3,4-dihydroxybutyrate formed from [1,2-13 C 2 ]GHB is 55 % M2 and 45 % unlabelled. The interpretation of these data is presented in the Discussion.
Fates of 4-hydroxy-4-phosphobutyryl-CoA
In our previous study [10] , we showed that 4-phosphoacyl-CoAs with more that four carbons (in the acyl group) are intermediates in the isomerization of 4-hydroxyacyl-CoAs to 3-ketoacylCoAs which are normal products of fatty acid β-oxidation. In the case of 4-hydroxy-4-phospho- 
Metabolism of GHB in perfused rat hearts
In hearts perfused with recirculating perfusate containing 1 mM [ 13 C 4 ]GHB, the very low uptake of the substrate was not measurable with precision. The mass isotopomer distribution of succinate (M1 = 2.0 + − 0.5 %, M2 = 0.43 + − 0.20 %, M3 = 0.25 + − 0.07 %, M4 = 1.0 + − 0.2 %; means + − S.E.M., n = 6) shows that relative anaplerosis from GHB was only approximately 1 % compared with 8 % in liver. Thus very little GHB is metabolized in the heart via the CAC. The only detected substantial labelling of a metabolite was the M2 enrichment of glycolate (27 + − 9 %). This shows that a small amount of GHB undergoes normal β-oxidation in the heart. Also, unlabelled glycolate was formed from endogenous substrates. The enrichment of acetyl-CoA was only 0.5 + − 0.4 (n = 6).
DISCUSSION
New pathways of GHB metabolism in liver
The present study identified a number of processes through which GHB is metabolized in liver, in addition to entry into the CAC via succinate. The identification of processes was based on metabolomics and mass isotopomer distribution of metabolites labelled from commercial and custom-synthesized labelled substrates. Although new processes were identified, the only measurable flux was the uptake of GHB by the perfused livers. This is because no end metabolite accumulated. Also, the labelling of 13 CO 2 was too low to be measured because of (i) the large pool of CO 2 + bicarbonate in the perfusate, and (ii) the gassing of the perfusate with 1 litre of 95 % O 2 + 5 % CO 2 per min. The 13 C label from GHB was found in a number of standard components of intermediary metabolism: CAC intermediates, glutamate, GABA, formate, propionyl-CoA and acetyl-CoA (reflected by the low labelling of acetate). However, we showed that the label of GHB passes through non-standard CoA esters, some of which were identified as such (γ -hydroxybutyryl-CoA, 4-hydroxy-4-phosphobutyrylCoA, compounds 2 and 3 respectively in Figure 6 ), whereas others were identified from the corresponding free acids (4-hydroxycrotonyl-CoA, 2,4-dihydroxybutyryl-CoA, 3,4-dihydroxybutyryl-CoA, 3-hydroxypropionyl-CoA and glycolylCoA, compounds 7, 4, 8, 5/5 and 10 respectively in Figure 6 ).
From all of the labelling data, especially those obtained with [1,2-13 C 2 ]GHB and [3,4-13 C 2 ]GHB, one can construct a scheme of GHB catabolism via β-oxidation and via two processes that remove C-1 or C-4 of GHB. This scheme is presented in two ways. First, Figure 6 , in which C-1 + C-2 of GHB are shown as tall characters, whereas C-3 + C-4 are shown as short bold characters, presents the complete scheme in detail. Secondly, Figure 7 is a simplified version of Figure 6 . In the following description, the labelling pattern of CoA esters discussed was inferred from the labelling pattern of the corresponding free acids assayed in the perfusate.
The α-oxidation process ( Figure 6 ) goes from γ -hydroxybutyryl-CoA to 2,4-dihydroxybutyryl-CoA to 3-hydroxypropionyl-CoA + formate (compounds 2→4→5 + 6). Through this Figure 6 , compounds 10→6) [29] .
Lastly, a process that removes C-4 of GHB branches off from the β-oxidation pathway: 3,4-dihydroxybutyryl-CoA to 3-hydroxypropionyl-CoA ( Figure 6, compounds 8→5 This scheme explains why the production of M1 formate ( Figure 4A ) is much greater from [3,4- 13 C 2 ]GHB than from [1,2-13 C 2 ]GHB. This is because formate is formed from the catabolism of glycolyl-CoA ( Figure 6 , compounds 10 and 6 ) [29] . The latter is M2 labelled from [3,4- 13 C 2 ]GHB, but unlabelled from [1,2-13 C 2 ]GHB. The scheme also explains why, in a liver perfused with 4-hydroxycrotonate (compound 12), we detected 3,4-dihydroxybutyrate (compound 8), but no 2,4-dihydroxybutyrate (compound 4).
Because of the complexity of Figure 6 , we present a simplified description of its conclusions in This appears as an α-oxidation sequence because it involves (i) the addition of a hydroxy group on C-2 of γ -hydroxybutyrylCoA, and (ii) the removal of C-1 of 2,4-dihydroxybutyryl-CoA, presumably as formate. Fatty acid α-oxidation reactions are usually detected by the formation of labelled formate from a fatty acid labelled on C-1 [30] [31] [32] [33] [34] . However, labelled formate is also formed from processes unrelated to α-oxidation. For example, the high production of [
13 C]formate from [3,4-13 C 2 ]GHB ( Figure 4A ) probably results mostly from the catabolism of glycolyl-CoA [35] (see Figure 6 ). Also, we have shown previously that part of the label from anaplerotic compounds (such as [ 13 C 3 ] propionylCoA derived from [ 13 C 5 ]laevulinate [36] ) is found in glycine and formate. Because GHB is anaplerotic via succinate [8] ( Figure 6 , top left), labelled formate should arise from 13 C-labelled GHB. Therefore we cannot infer α-oxidation processes in the degradation of [1,2-13 C 2 ]GHB or [3,4-13 C 2 ]GHB solely from the production of [ 13 C]formate. However, we can infer an α-oxidation process from specific precursor-to-product relationships between the mass isotopomer distributions of sequential metabolites, besides formate. For example, in perfusions with [1,2-13 C 2 ]GHB, M2 γ -hydroxybutyryl-CoA, M2 2,4-dihydroxybutyryl-CoA and M1 3-hydroxypropionyl-CoA are in a clear precursor-product relationship ( Figure 6 , compounds 2, 4 and 5, tall carbons). As in other α-oxidation processes, the sequence involves the addition of a hydroxy group on C-2 of γ -hydroxybutyryl-CoA (compound 2) to form 2,4-dihydroxybutyryl-CoA (compound 4). Thus the removal of C-1 of GHB in the sequence of compounds 2 to 4 to 5 + 6 is clearly an α-oxidation process.
Secondly, let us consider the removal of C-4 of GHB in the sequence 3,4-dihydroxybutyryl-CoA to 3-hydroxypropionylCoA ( Figure 6, compounds 8 and 5 ). In perfusions with [3,4- 13 C 2 ]GHB, M2 3,4-dihydroxybutyryl-CoA and M1 3-hydroxypropionyl-CoA are in a clear precursor-product relationship ( Figure 6 , compounds 8 and 5 , short bold carbons). The production of compound 5 from compound 8 is also confirmed by data from perfusions with unlabelled 4-hydroxycrotonate (Figure 3 ). This compound forms 3,4-dihydroxybutyrate and 3-hydroxypropionate, but not 2,4-dihydroxybutyrate (Figures 3 and 6) . Therefore there must be a sequence of unknown reactions that remove C-4 of dihydroxybutyryl-CoA, forming 3-hydroxypropionyl-CoA and probably either formate or CO 2 . This is why, in Figure 6 , we label the conversion of 8 into 5 as 'removal of C-4'. The removal of C-4 probably involves the conversion of the primary alcohol function into a carboxy group or a carboxyl-CoA, followed by the removal of C-4 as CO 2 or formate.
Reversibility of some reactions of GHB β-oxidation
The mass isotopomer distribution of 3,4-dihydroxybutyrate formed from [3,4- 13 C 2 ]GHB was mostly M2, with a trace of endogenous unlabelled M ( Figure 5 ). In contrast, 3,4-dihydroxybutyrate formed from [1,2-13 C 2 ]GHB was 55 % M2 and 45 % unlabelled. This led us to hypothesize that C-1 + C-2 of 3,4-dihydroxybutyryl-CoA ( Figure 6 , compound 8) exchange with unlabelled acetyl-CoA (compound 11) via the putative 4-hydroxy-3-ketobutyryl-CoA (compound 9) and the reactions catalysed by 3-hydroxyacyl-CoA dehydrogenase and 3-ketoacyl-CoA thiolase.
To check this hypothesis, we perfused one liver with unlabelled GHB + unlabelled glucose + 5 mM [ 13 C 2 ]acetate (a precursor of M2 acetyl-CoA). We found that 3,4-dihydroxybutyrate was 12 % M2 labelled, whereas 2,4-dihydroxybutyrate was unlabelled. This confirmed the isotopic exchange of C-1 + C-2 of 3,4-dihydroxybutyryl-CoA with acetyl-CoA via 3-hydroxyacylCoA dehydrogenase + thiolase.
Conclusions
The present study shows that the metabolism of GHB differs from that of longer-chain 4-hydroxyacids that we described previously [10] . First, as shown by others, one fate of GHB is its oxidation to a dicarboxylic acid, succinate, which is an intermediate of the CAC. There is no equivalent process in the fates of longerchain 4-hydroxyacids. We had shown that the 4-hydroxyacids with five of more carbons are catabolized by two pathways: (i) an isomerization pathway to 3-hydroxyacyl-CoAs via 4-phosphoacyl-CoAs followed by β-oxidation degradation, and (ii) sequential β-oxidation, α-oxidation and β-oxidation steps. Both pathways lead to acetyl-CoA, formate and propionyl-CoA. We were able to assess the metabolism of the longer 4-hydroxyacids from (i) the uptake of the substrate, and (ii) the ratio of pathway fluxes (A/B) by the labelling ratio (M2 acetyl-CoA)/(M1 acetylCoA) measured in the presence of 4-hydroxy-[3,4-13 C 2 ]nonanoic acid. This type of calculation is not possible for GHB catabolism because it is catabolized by five pathways, none of which yields a product that accumulates.
4-Phosphobutyryl-CoA accumulates in much lower concentrations in livers perfused with GHB than in livers perfused with longer-chain 4-hydroxyacids (C 5 to C 11 ). Thus one cannot identify intermediates of its catabolism. The 2 H-labelling of 4-phosphobutyryl-CoA in perfusions conducted in 100 % 2 H 2 O buffer (as was observed with longer-chain 4-phosphoacyl-CoAs) suggests that it is sequentially metabolized to 3-hydroxybutyrylCoA, acetoacetyl-CoA and acetyl-CoA. It is not possible to separate 3-hydroxybutyryl-CoA from the γ -hydroxybutyrylCoA present at fairly high concentration. The 6-fold higher concentration of M1 formate in perfusions with [3,4- 13 C 2 ]GHB compared with [1,2-13 C 2 ]GHB ( Figure 4A ) suggests that the β-oxidation of GHB ( Figure 6 ) is its most abundant catabolic pathway. This is because M1 formate derives mostly from the oxidation of glycolate formed from C-3 + C-4 of GHB.
The groups of Pollitt and Vamecq had hypothesized that GHB undergoes β-oxidation [5, 6] and α-oxidation [6] because of the excretion of glycolate, 2,4-dihydroxybutyrate and 3-hydroxypropionate by patients affected by an inborn disorder of succinic semialdehyde dehydrogenase [3] . Our data confirm and extend these hypotheses by the identification and characterization of two parallel β-oxidation processes and two parallel processes which remove C-1 or C-4 of GHB and yield 3-hydroxypropionate. These newly identified pathways may play a role in the physiopathology of succinic semialdehyde dehydrogenase deficiency. Lastly, the present study illustrates the potential of the combination of metabolomics and mass isotopomer analysis for pathway discovery [14] .
